Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Rhea-AI Summary
Lipocine (NASDAQ:LPCN), a biopharmaceutical company focused on oral drug delivery, announced that management will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Company Showcase on bWednesday, May 20, 2026 at 3:00 PM ET
Investors can register online and view the fireside chat.
Positive
- None.
Negative
- None.
News Market Reaction – LPCN
In the May 18 session, LPCN declined 2.21%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-05-07 | Earnings & clinical update | Negative | -0.8% | Q1 results and confirmation that LPCN 1154 Phase 3 primary endpoint was not met. |
| 2026-04-02 | Phase 3 topline data | Negative | -77.8% | Topline Phase 3 PPD data for LPCN 1154 showing primary endpoint not met in full set. |
| 2026-03-10 | Full-year earnings | Positive | +2.9% | 2025 results, cash of $14.9M, ATM use raising cash, and pipeline progress update. |
| 2026-02-18 | Phase 3 LPLV | Positive | -1.3% | Completion of Last Patient Last Visit in LPCN 1154 pivotal Phase 3 with favorable safety. |
| 2026-01-20 | Trial enrollment complete | Positive | -10.9% | Completion of enrollment and dosing of 90 patients in Phase 3 LPCN 1154 PPD trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News tied to LPCN 1154’s clinical outcomes has often seen aligned downside reactions, while operational or pipeline updates without major surprises have produced smaller, sometimes divergent moves.
Over the last few months, Lipocine’s story centered on its Phase 3 program for LPCN 1154 in postpartum depression and its financial footing. Enrollment and Last Patient Last Visit were completed in early 2026, followed by topline data on April 2 showing the primary endpoint was not met and a sharp -77.84% reaction. Subsequent Q1 results on May 7 reiterated the trial outcome but highlighted $24.7M in cash. Today’s conference participation fits into ongoing investor outreach after these developments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside Chat Details:
Time: 3:00 PM ET
Date: Wednesday, May 20, 2026
Investors can register for the conference and view the fireside chat here.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-agps-annual-virtual-healthcare-company-showcase-302773335.html
SOURCE Lipocine Inc.